Caspofungin Acetate
NDC Package 69097-366-37

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Caspofungin Acetate is caspofungin is used to treat a variety of fungal infections. Marketed by Cipla Usa Inc., this product is identified by NDC 69097-366 and is authorized under FDA application ANDA209489.

Identification & Billing

NDC Package Code
69097-366-37
Package Description
10 mL in 1 VIAL, SINGLE-DOSE
Product Code
69097-366
11-Digit Billing Format
69097036637

Clinical Specifications

Proprietary Name
Caspofungin Acetate
Dosage Form
-
Usage Information
Caspofungin is used to treat a variety of fungal infections. Caspofungin belongs to a class of drugs known as echinocandins. It works by stopping the growth of fungi.

Regulatory & Marketing

Labeler Name
Cipla Usa Inc.
FDA Application #
ANDA209489
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
07-12-2018
End Marketing Date
08-31-2021
Listing Expiration
08-31-2021
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 69097-366-37 identifies a specific commercial package of 10 ml in 1 vial, single-dose of Caspofungin Acetate, labeled by Cipla Usa Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Cipla Usa Inc. on July 12, 2018. The current certification is valid through August 31, 2021.

What are the primary indications for this medication?

Caspofungin is used to treat a variety of fungal infections. Caspofungin belongs to a class of drugs known as echinocandins. It works by stopping the growth of fungi.

How is this Cipla Usa Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 69097036637. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
69097-366-37
11-Digit CMS (5-4-2)
69097-0366-37

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.